DE10003835A1 - Formulations in dehydration conditions - Google Patents
Formulations in dehydration conditionsInfo
- Publication number
- DE10003835A1 DE10003835A1 DE10003835A DE10003835A DE10003835A1 DE 10003835 A1 DE10003835 A1 DE 10003835A1 DE 10003835 A DE10003835 A DE 10003835A DE 10003835 A DE10003835 A DE 10003835A DE 10003835 A1 DE10003835 A1 DE 10003835A1
- Authority
- DE
- Germany
- Prior art keywords
- creatine
- formulations
- dehydration
- formulations according
- water
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 22
- 238000009472 formulation Methods 0.000 title claims abstract description 18
- 230000018044 dehydration Effects 0.000 title claims abstract description 17
- 238000006297 dehydration reaction Methods 0.000 title claims abstract description 17
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 claims abstract description 45
- 229960003624 creatine Drugs 0.000 claims abstract description 20
- 239000006046 creatine Substances 0.000 claims abstract description 20
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 8
- MEJYXFHCRXAUIL-UHFFFAOYSA-N 2-[carbamimidoyl(methyl)amino]acetic acid;hydrate Chemical compound O.NC(=N)N(C)CC(O)=O MEJYXFHCRXAUIL-UHFFFAOYSA-N 0.000 claims abstract description 6
- 229960004826 creatine monohydrate Drugs 0.000 claims abstract description 6
- 239000012530 fluid Substances 0.000 claims abstract description 6
- DLNGCCQFGNSBOP-UHFFFAOYSA-N 2-[carbamimidoyl(methyl)amino]acetic acid;2-oxopropanoic acid Chemical compound CC(=O)C(O)=O.NC(=N)N(C)CC(O)=O DLNGCCQFGNSBOP-UHFFFAOYSA-N 0.000 claims abstract description 5
- 235000010323 ascorbic acid Nutrition 0.000 claims abstract description 4
- 239000011668 ascorbic acid Substances 0.000 claims abstract description 4
- 239000003978 infusion fluid Substances 0.000 claims abstract description 4
- 229940072107 ascorbate Drugs 0.000 claims abstract description 3
- 239000002775 capsule Substances 0.000 claims abstract description 3
- 239000000843 powder Substances 0.000 claims abstract description 3
- 239000003826 tablet Substances 0.000 claims abstract description 3
- 238000009098 adjuvant therapy Methods 0.000 claims 1
- 208000005156 Dehydration Diseases 0.000 abstract description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 11
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 238000001802 infusion Methods 0.000 description 6
- 210000003205 muscle Anatomy 0.000 description 6
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 230000007423 decrease Effects 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- 206010016807 Fluid retention Diseases 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000001103 potassium chloride Substances 0.000 description 2
- 235000011164 potassium chloride Nutrition 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
- 241000881711 Acipenser sturio Species 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 239000012891 Ringer solution Substances 0.000 description 1
- 239000008156 Ringer's lactate solution Substances 0.000 description 1
- 230000009056 active transport Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 210000000476 body water Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 230000001447 compensatory effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 239000007911 effervescent powder Substances 0.000 description 1
- 238000004146 energy storage Methods 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000001540 sodium lactate Substances 0.000 description 1
- 235000011088 sodium lactate Nutrition 0.000 description 1
- 229940005581 sodium lactate Drugs 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Gegenstand der vorliegenden Erfindung sind Formulierungen bei Dehydratationszuständen.The present invention relates to formulations in Dehydration conditions.
Bei degenerativen Prozessen, insbesondere während der Alterung des Menschen spielt die Abnahme der Körpersubstanz eine bedeutende Rolle. Neben einer Verringerung der Muskelmasse kommt es dabei zu einer Dehydratation, die meist auf eine unzureichende Flüssigkeitsaufnahme zurückzuführen ist, zum Teil aber auch mit veränderten bzw. reduzierten metabolischen Prozessen einhergeht.In degenerative processes, especially during the aging of the Humans play a significant role in the decline of the body substance. In addition to a reduction in muscle mass it comes to a Dehydration, mostly due to inadequate fluid intake is due, but partly also with changed or reduced associated with metabolic processes.
Unter Dehydratation (Hypohydratation) versteht man ganz allgemein die Abnahme des Körperwassers, dessen Menge beim durchschnittlichen gesunden Erwachsenen 55-60% der Körpersubstanz ausmacht. Dehydratationserscheinungen sind in der Regel auf eine gestörte renale, gastrointestinale, pulmonale bzw. perkutane Wasserabgabe ohne eine entsprechende ausgleichende Zufuhr zurückzuführen. Mit dem Wasserverlust geht meist auch ein signifikanter Natriumverlust einher, was zu einem gravierenden und lebensbedrohenden Volumenmangel führen kann.By dehydration (Hypohydratation) one understands generally the Decrease in body water, its amount in the average healthy adult makes up 55-60% of the body substance. Dehydration symptoms are usually due to a disturbed renal, Gastrointestinal, pulmonary or percutaneous water delivery without one corresponding compensatory supply due. With the Water loss is usually accompanied by a significant loss of sodium, which lead to a serious and life-threatening lack of volume can.
Die Folge ist typischerweise eine allgemein verminderte körperliche und geistige Leistungsfähigkeit.The consequence is typically a generally diminished physical and mental capacity.
Mit zunehmendem Alter verändert sich aber auch der kolloidale Zustand der Proteinkörper, bspw. des Kollagens, derart, dass die Wasserbindungsfähigkeit abnimmt und der Gewebsturgor verringert wird. Die Folge sind atrophische Veränderungen.With increasing age, however, the colloidal state also changes the protein body, for example of the collagen, such that the Water binding ability decreases and the tissue sturgeon is reduced. The result is atrophic changes.
Um diesen Zustand zu bessern, wird als therapeutische Maßnahme vor allem das Auffüllen der Flüssigkeitsdepots des Körpers durch Infusion von Ringerlösungen verschiedenster Zusammensetzungen angestrebt, wodurch zumindest der akute Wassermangel meist auch beseitigt wird. Der positive Effekt geht aber schon nach kurzer Zeit wieder verloren und es stellt sich wieder der alte dehydratisierte Zustand ein, der erneute Infusionen notwendig macht.To improve this condition is considered a therapeutic measure in particular, the filling of the fluid deposits of the body by infusion of Ringer solutions of various compositions sought, causing at least the acute lack of water is usually also eliminated. The positive Effect is lost after a short time and it turns out again the old dehydrated state, the re-infusions necessary.
Die eigentliche Ursache der Austrocknungserscheinungen wird mit den bisherigen Maßnahmen nicht beseitigt.The actual cause of the dehydration phenomena is with the Previous measures not eliminated.
Die Aufgabe der vorliegenden Erfindung bestand somit darin, Formulierungen bei Dehydratationszuständen bereitzustellen, die eine bessere Wasseraufnahme in die Körpergewebe und vor allem in die Muskulatur bewirken.The object of the present invention was therefore to To provide formulations in dehydration conditions that have a better water absorption in the body tissues and especially in the Cause muscle.
Gelöst wurde diese Aufgabe durch Formulierungen bei Dehydratationszuständen, die Kreatin und/oder Kreatin-derivate enthalten.This task was solved by formulations Dehydration conditions containing creatine and / or creatine derivatives.
Überraschenderweise hat sich gezeigt, dass mit den erfindungsgemäßen Formulierungen tatsächlich nicht nur eine bessere und verstärkte Wasseraufnahme in die verschiedenen Körpergewebe zu erzielen ist, sondern dass das Wasser in den Geweben auch signifikant länger gespeichert wird.Surprisingly, it has been found that with the invention In fact, phrasing is not just a better and stronger one To absorb water in different body tissues but that the water in the tissues also significantly longer is stored.
Kreatin ist eine natürliche, als bekannter Energiespeicher vor allem im Muskelgewebe vorkommende Verbindung, die nicht toxisch ist, von den Nieren zum harngängigen Kreatinin katabolisiert wird und eine ganz allgemein gute Verträglichkeit aufweist. Von Kreatin ist ebenfalls bekannt, dass es pro Gramm 23 ml Wasser zu binden vermag (vgl. Prof. Dr. Neumann, Institut für angewandte Trainingswissenschaften der Universität Leipzig: Creatinabol-Studie).Creatine is a natural, known energy storage especially in the Muscle tissue occurring compound that is non-toxic, from the Kidneys to urinary creatinine is catabolized and a whole generally good compatibility. Creatine is also known that it is capable of binding 23 ml of water per gram (cf. Prof. Dr. Neumann, Institute of Applied Exercise Science of University of Leipzig: Creatinabol study).
In einer Reihe von Untersuchungen wurde gefunden, dass bei Einnahme von Kreatin das Körpergewicht zunimmt, wobei ein Teil dieser Gewichtszunahme auf einer signifikanten Zunahme der Muskelmasse beruht; zum anderen aber vollzieht sich eine Wassereinlagerung in die unterschiedlichsten Gewebearten, ein Effekt der neben der ebenfalls durchaus wünschenswerten Zunahme der Muskelmasse vor allem für den alten Menschen von großem Nutzen ist.In a series of studies it was found that when ingested Of creatine the body weight increases, being a part of this Weight gain on a significant increase in muscle mass is based; but on the other hand, a water retention takes place in the different types of fabric, an effect of addition to the same quite desirable increase in muscle mass especially for the old people is of great benefit.
Modelle erklären den Effekt der Wassereinlagerung in die Gewebe damit, dass bei der Supplementation von Kreatin und/oder einem seiner physiologisch geeigneten Derivate und im Zuge aktiver Transportvorgänge gleichzeitig auch Natrium-Chlorid in die Zellen transportiert wird, was eine vermehrte Aufnahme von Wasser in die Muskelzellen bewirkt.Models explain the effect of water retention in tissues, that in the supplementation of creatine and / or one of his Physiologically suitable derivatives and in the course of active transport operations At the same time also sodium chloride is transported into the cells, what a Increased absorption of water in the muscle cells causes.
Als besonders geeignete Kreatin-Verbindungen haben sich erfindungsgemäß das Kreatin-monohydrat, aber auch Kreatinsalze wie Kreatin-ascorbat und Kreatin-pyruvat erwiesen, die natürlich auch in beliebigen Mischungen vorliegen können.Particularly suitable creatine compounds have become according to the invention, creatine monohydrate, but also creatine salts Creatine ascorbate and creatine pyruvate, which are naturally also found in may be present any mixtures.
Dabei ist die Applikationsform völlig unbeschränkt, doch haben sich in Abhängigkeit vom jeweiligen Indikationsgebiet Infusionslösungen und Getränke, Tabletten, Kapseln und Pulver als sehr vorteilhaft bei der Behandlung von Dehydratationserscheinungen gezeigt. Infusionen und Getränke sind vor allem dazu geeignet, akute Dehydratationssymptome in kurzer Zeit erfolgreich zu revertieren.The form of application is completely unlimited, but have become in Dependence on the respective therapeutic area Infusion solutions and Beverages, tablets, capsules and powders are very beneficial in the Treatment of dehydration phenomena shown. Infusions and Beverages are especially suitable for acute dehydration symptoms in a short time to revert successfully.
Zu berücksichtigen ist dabei in jedem Fall, dass die erfindungsgemäßen Formulierungen in einer Menge gegeben werden, die eine empfohlene Tagesdosis von 4 g Kreatin nicht überschreiten. Dabei ist die Obergrenze von 4 g als Gesamttagesdosis zu beachten, was insbesondere bei der gleichzeitigen Applikation von Kreatin-enthaltenden Infusionen, der Aufnahme von Kreatin-haltigen Getränken und der Einnahme von festen Kreatin-haltigen erfindungsgemäßen Formulierungen berücksichtigt werden muss.It should be noted in any case that the invention Formulations are given in an amount that is a recommended Do not exceed daily dose of 4 g creatine. Here is the upper limit of 4 g as a total daily dose to observe, which in particular in the simultaneous administration of creatine-containing infusions, the Intake of creatine-containing drinks and the intake of solid Creatine-containing formulations of the invention considered must become.
Die Formulierungen gemäß Erfindung, für die orale Gaben vorzuziehen sind, finden bevorzugt Verwendung bei Alterspatienten mit meist reduziertem Durstempfinden und einer damit verbundenen, eingeschränkten Flüssigkeitszufuhr, bei Immobilitätspatienten, die aufgrund ihrer eingeschränkten Bewegungsmöglichkeiten einer gesteigerten Reduktion der Muskelmasse unterliegen und bei Patienten mit gestörter Flüssigkeitsresorption, also allgemein bei Patienten, die verstärkte Dehydratationssymptome aufweisen.The formulations according to the invention are preferable for oral administration are preferred to use in older patients with mostly reduced thirst and an associated, limited fluid intake, in immobility patients who due to their limited movement possibilities one subject to increased reduction of muscle mass and in patients with impaired fluid resorption, that is generally in patients who have increased dehydration symptoms.
Nachfolgend sind beispielhaft typische erfindungsgemäße Formulierungen bei Dehydratationszuständen aufgeführt. The following are exemplary typical formulations of the invention listed under dehydration conditions.
Infusionsmenge max. 2000 ml pro 24 Std. i. v.Infusion rate max. 2000 ml per 24 hours i. v.
Infusionsmenge max. 1500 ml pro 24 Std. i. v.Infusion rate max. 1500 ml per 24 hours i. v.
Claims (6)
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10003835A DE10003835A1 (en) | 2000-01-28 | 2000-01-28 | Formulations in dehydration conditions |
| AU2001244108A AU2001244108A1 (en) | 2000-01-28 | 2001-01-26 | Formulations for states of dehydration |
| PCT/EP2001/000863 WO2001054676A2 (en) | 2000-01-28 | 2001-01-26 | Formulations for states of dehydration |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10003835A DE10003835A1 (en) | 2000-01-28 | 2000-01-28 | Formulations in dehydration conditions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE10003835A1 true DE10003835A1 (en) | 2001-08-16 |
Family
ID=7629123
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE10003835A Withdrawn DE10003835A1 (en) | 2000-01-28 | 2000-01-28 | Formulations in dehydration conditions |
Country Status (3)
| Country | Link |
|---|---|
| AU (1) | AU2001244108A1 (en) |
| DE (1) | DE10003835A1 (en) |
| WO (1) | WO2001054676A2 (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10215007A1 (en) * | 2002-04-05 | 2003-10-16 | Degussa Bioactives Deutschland | Use of creatine pyruvate to increase endurance during high-intensity physical interval workouts |
| DE102004009962A1 (en) * | 2004-03-01 | 2005-09-22 | Degussa Ag | Use of guanidine compounds as physiological restorative in the form of nutritional supplements, feed additives, in cosmetic preparations and as plant strengthening agents |
| US8501810B2 (en) | 2004-06-09 | 2013-08-06 | Alzchem Trostberg Gmbh | Guanidino acetic acid used as an animal food additive |
| WO2019185408A1 (en) | 2018-03-27 | 2019-10-03 | Evonik Degussa Gmbh | Use of guanidinoacetic acid and/or creatine in aquaculture |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1688139A1 (en) * | 2000-09-14 | 2006-08-09 | Board of Regents of the University of Nebraska | Creatine ester pronutrient compounds and formulations |
| US20030212136A1 (en) | 2001-09-14 | 2003-11-13 | Vennerstrom Jonathan L. | Creatine ester pronutrient compounds and formulations |
| DE102007004781A1 (en) | 2007-01-31 | 2008-08-07 | Alzchem Trostberg Gmbh | Use of guanidinoacetic acid (salts) for the preparation of a health-promoting agent |
| US9233099B2 (en) | 2012-01-11 | 2016-01-12 | University Of Cincinnati | Methods of treating cognitive dysfunction by modulating brain energy metabolism |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU7584891A (en) * | 1990-03-19 | 1991-10-21 | Brigham And Women's Hospital | Treatment of osmotic disturbance with organic osmolytes |
| US5397786A (en) * | 1993-01-08 | 1995-03-14 | Simone; Charles B. | Rehydration drink |
| CN1076343C (en) * | 1996-12-20 | 2001-12-19 | Skw特罗斯特贝格股份公司 | Creatine pyruvates and method for their production |
| WO1998038183A1 (en) * | 1997-02-26 | 1998-09-03 | Skw Trostberg Aktiengesellschaft | Creatine-ascorbates, production process |
| DE19929994A1 (en) * | 1998-07-09 | 2000-01-13 | Sueddeutsche Kalkstickstoff | Treatment of skeletal muscle dystrophies and atrophies using creatine |
| DE19841385A1 (en) * | 1998-09-10 | 2000-03-16 | Sueddeutsche Kalkstickstoff | Use of creatine and/or creatine derivatives as moisturizers in cosmetic compositions |
| WO2001003325A2 (en) * | 1999-06-30 | 2001-01-11 | Skw Trostberg Aktiengesellschaft | Use of creatine and/or creatine derivatives for treating feelings of ill-health in women |
-
2000
- 2000-01-28 DE DE10003835A patent/DE10003835A1/en not_active Withdrawn
-
2001
- 2001-01-26 WO PCT/EP2001/000863 patent/WO2001054676A2/en not_active Ceased
- 2001-01-26 AU AU2001244108A patent/AU2001244108A1/en not_active Abandoned
Non-Patent Citations (1)
| Title |
|---|
| Diss. Abstr. Int., B 1999, 59(12), 6247 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10215007A1 (en) * | 2002-04-05 | 2003-10-16 | Degussa Bioactives Deutschland | Use of creatine pyruvate to increase endurance during high-intensity physical interval workouts |
| DE102004009962A1 (en) * | 2004-03-01 | 2005-09-22 | Degussa Ag | Use of guanidine compounds as physiological restorative in the form of nutritional supplements, feed additives, in cosmetic preparations and as plant strengthening agents |
| US8501810B2 (en) | 2004-06-09 | 2013-08-06 | Alzchem Trostberg Gmbh | Guanidino acetic acid used as an animal food additive |
| WO2019185408A1 (en) | 2018-03-27 | 2019-10-03 | Evonik Degussa Gmbh | Use of guanidinoacetic acid and/or creatine in aquaculture |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2001244108A1 (en) | 2001-08-07 |
| WO2001054676A2 (en) | 2001-08-02 |
| WO2001054676A3 (en) | 2002-05-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE212007000001U1 (en) | Combination preparation to improve sperm quality | |
| DE3875867T2 (en) | CALCIUM ADDITIVES. | |
| DE60125191T2 (en) | COMPOSITIONS AND METHODS FOR IMPROVING CARDIOVASCULAR FUNCTION | |
| DE10003835A1 (en) | Formulations in dehydration conditions | |
| DE2414593A1 (en) | MEDICINAL PRODUCTS AND METHOD FOR ITS MANUFACTURING | |
| DE3880587T2 (en) | USE OF CERTAIN CALCIUM-CITRATE MALATES FOR THE PRODUCTION OF A PHARMACEUTICAL PREPARATION FOR THE TREATMENT OF OSTEOPOROSIS. | |
| DE4413839C1 (en) | combination preparation | |
| DE19910682B4 (en) | Use of a combination preparation for the therapy of fibrate-induced hyperhomocysteinemia | |
| DE1767017A1 (en) | Iron preparation | |
| EP2558084A2 (en) | Combination of vitamin k and nicotinamide | |
| CA2314817C (en) | Synergistic agents for enhancing tissue repair | |
| DE102004052882A1 (en) | Liquid food auxiliary agent, to e.g. stabilize immune system, comprises fruit concentrates (e.g. concentrates of red grape, apple, rose hip, peach and red currant), ascorbic acid, dextrose-monohydrate; maleic acid; and nitrogen | |
| EP1492419A1 (en) | Use of creatine pyruvate for increasing stamina during highly intensive intermittent physical exertion | |
| WO2014087006A1 (en) | Method and device for administering hypoxic and hyperoxic gas | |
| DE60020888T2 (en) | EXTRACTS FROM HERBS FOR THE TREATMENT OF COGNITIVE DISTURBANCES DUE TO ESTROGEN LOSS | |
| EP2072046A1 (en) | Use of a hydrocarbon-containing preparation for preventing or treating cardiac-circulatory diseases, diabetes, osteoporosis and chronic liver failure | |
| DE102004008375B4 (en) | Use of physiologically acceptable ascorbate compounds in combination with a sympathomimetic as a local therapeutic agent for mucous membranes of the respiratory tract | |
| CH679372A5 (en) | ||
| EP0291751B1 (en) | Pharmaceutical mixture preparation | |
| DE10160485A1 (en) | Use of creatine and / or one of its physiologically suitable derivatives for the prevention or relief of non-disease-related impairments and / or disorders of muscle function | |
| DE19929994A1 (en) | Treatment of skeletal muscle dystrophies and atrophies using creatine | |
| EP1563743B1 (en) | Composition comprising a caffeine-containing substance, particularly guarana | |
| DE60109184T2 (en) | MEDICAL COMPOSITION AND, IN PARTICULAR, ITS USE IN LIQUID THERAPY | |
| AT513541A1 (en) | Fructose, sucrose, artificial sweetener and gluten and lactose free energy drink | |
| Hoppe-Tichy et al. | Stabilität von Voriconazol-Konzentrat und Voriconazol-Infusionsbeuteln |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| OP8 | Request for examination as to paragraph 44 patent law | ||
| 8139 | Disposal/non-payment of the annual fee |